The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
Open accessAbstract
Summary: Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by chronic, uncontrolled complement activation resulting in elevated intravascular haemolysis and morbidities, including fatigue, dyspnoea, abdominal pain, pulmonary hypertension, thrombotic events (TE s) and chronic kidney disease (CKD). The long‐term safety and efficacy of eculizumab, a humanized monoclonal antibody that inhibits terminal complement activation, was investigated in 195 patients over 66 months. Four patient deaths were reported, all unrelated to treatment, resulting in a 3‐year survival estimate of 97·6%. All patients showed a reduction in lactate dehydrogenase levels, which was sustained over the course of treatment (median reduction of 86·9% at 36 months), reflecting inhibition of chronic haemolysis. TE s decreased by 81·8%, with 96·4% of patients remaining free of TE s. Patients also showed a time‐dependent improvement in renal function: 93·1% of patients exhibited improvement or stabilization in CKD score at 36 months. Transfusion independence increased by 90·0% from baseline, with the number of red blood cell units transfused decreasing by 54·7%. Eculizumab was well tolerated, with no evidence of cumulative toxicity and a decreasing occurrence of adverse events over time. Eculizumab has a substantial impact on the symptoms and complications of PNH and results a significant improvement in patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationThe Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Self-citationTakeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Natural History of Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Lewis, S. M., Bessler, M., Luzzatto, L., & Dacie, J. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331904 · Cited by 907
Self-citationRother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Although eculizumab suppresses the terminal complement system, the proximal complement system, responsible for opsonization of microorganisms and clearance of immune complexes, remains intact and fully functional (Rother et al, 2007).”
BackgroundInfectious diseases associated with complement deficiencies
Figueroa, J. E., & Densen, P. (1991) · Clinical Microbiology Reviews · doi:10.1128/cmr.4.3.359 · Cited by 729
Brodsky, R. A., Young, N. S., Antonioli, E., Risitano, A. M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.-L., et al. (2008) · Blood · doi:10.1182/blood-2007-06-094136 · Cited by 652
Self-citationHillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
Self-citationHillmen, P., Muus, P., Dührsen, U., Risitano, A. M., Schubert, J., Luzzatto, L., Schrezenmeier, H., Szer, J., Brodsky, R. A., Hill, A., et al. (2007) · Blood · doi:10.1182/blood-2007-06-095646 · Cited by 579
Self-citationKelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Cohen, D. R., Gregory, W. M., & Hillmen, P. (2011) · Blood · doi:10.1182/blood-2011-02-333997 · Cited by 526
Self-citationParoxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors
Socié, G., Mary, J.-Y., de Gramont, A., Rio, B., Leporrier, M., Rose, C., Heudier, P., Rochant, H., Cahn, J.-Y., & Gluckman, E. (1996) · The Lancet · doi:10.1016/s0140-6736(95)12360-1 · Cited by 518
Self-citationParoxysmal nocturnal hemoglobinuria: natural history of disease subcategories
de Latour, R. P., Mary, J. Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Roth, S., de Guibert, S., Maury, S., Cahn, J. Y., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133918 · Cited by 378
Self-citationNatural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays
Moyo, V. M., Mukhina, G. L., Garrett, E. S., & Brodsky, R. A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04992.x · Cited by 264
Self-citationHow I treat paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2009) · Blood · doi:10.1182/blood-2009-03-195966 · Cited by 263
Self-citationNishimura, J.-I., Kanakura, Y., Ware, R. E., Shichishima, T., Nakakuma, H., Ninomiya, H., Decastro, C. M., Hall, S., Kanamaru, A., Sullivan, K. M., et al. (2004) · Medicine · doi:10.1097/01.md.0000126763.68170.46 · Cited by 261
Self-citationSustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
Hill, A., Hillmen, P., Richards, S. J., Elebute, D., Marsh, J. C., Chan, J., Mojcik, C. F., & Rother, R. P. (2005) · Blood · doi:10.1182/blood-2005-02-0564 · Cited by 212
Self-citationHeme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1
Nath, K. A., Vercellotti, G. M., Grande, J. P., Miyoshi, H., Paya, C. V., Manivel, J. C., Haggard, J. J., Croatt, A. J., Payne, W. D., & Alam, J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00471.x · Cited by 211
Hillmen, P., Elebute, M., Kelly, R., Urbano‐Ispizua, A., Hill, A., Rother, R. P., Khursigara, G., Fu, C., Omine, M., Browne, P., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21757 · Cited by 205
Self-citationThe management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
Kelly, R., Arnold, L., Richards, S. J., Hill, A., Bomken, C., Hanley, J. P., Loughney, A. D., Beauchamp, J., Khursigara, G., Rother, R. P., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08099.x · Cited by 167
Self-citationHill, A., Rother, R. P., Wang, X., Morris, Jr., Quinn‐Senger, K., Kelly, R., Richards, S. J., Bessler, M., Bell, L., Hillmen, P., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08096.x · Cited by 158
Self-citationThe kidneys in paroxysmal nocturnal hemoglobinuria
Clark, D. A., Butler, S., Braren, V., et al. (1981) · Blood · doi:10.1182/blood.v57.1.83.83 · Cited by 135
Hill, A., Sapsford, R. J., Scally, A., Kelly, R., Richards, S. J., Khurisgara, G., Sivananthan, M. U., & Hillmen, P. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09166.x · Cited by 104
Self-citationParoxysmal Nocturnal Hemoglobinuria from Bench to Bedside
Pu, J. J., & Brodsky, R. A. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00262.x · Cited by 84
Self-citationMcKeage, K. (2011) · Drugs · doi:10.2165/11208300-000000000-00000 · Cited by 76
Emadi, A., & Brodsky, R. A. (2009) · American Journal of Hematology · doi:10.1002/ajh.21506 · Cited by 55
Self-citationHill, A., Rother, R. P., & Hillmen, P. (2005) · PubMed · Cited by 44
Self-citationThe pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
Kelly, R. J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3334 · Cited by 42
Cited by
Paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2014) · Blood · doi:10.1182/blood-2014-02-522128 · Cited by 648
Self-citationInternational, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Complement in disease: a defence system turning offensive
Ricklin, D., Reis, E. S., & Lambris, J. D. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.70 · Cited by 550
Paroxysmal nocturnal haemoglobinuria
Hill, A., DeZern, A. E., Kinoshita, T., & Brodsky, R. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.28 · Cited by 448
Self-citationComplement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
Metadata
- Authors
- Hillmen, P., Muus, P., Röth, A., Elebute, M. O., Risitano, A. M., Schrezenmeier, H., Szer, J., Browne, P., Maciejewski, J. P., Schubert, J., Urbano‐Ispizua, A., de Castro, C., Socié, G., & Brodsky, R. A.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2013-04-25
- Volume
- 162
- Issue
- 1
- Pages
- 62-73
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2121920823
- Cited by
- 394
- References
- 30
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.